Also known as PNC27
A p53-derived membrane-targeting peptide studied for selective necrosis of cancer cells in preclinical models.
Research refreshed
PNC-27 is a designed peptide that joins a fragment of the p53 protein (the region that binds HDM-2) to a membrane-residency peptide that anchors it in the cell membrane. In preclinical studies it is reported to induce necrosis selectively in cancer cells — which display HDM-2 at the membrane — while sparing normal cells, by forming membrane pores rather than acting through the classic p53 transcriptional pathway. It is an early anticancer research peptide with no clinical data and no approval.
PNC-27 comes from the idea that the p53–HDM-2 interaction can be turned into a selective cancer-cell toxin. The peptide carries the p53 segment that binds HDM-2, attached to a “membrane-residency” peptide that lodges it in the plasma membrane. Cancer cells that present HDM-2 at their surface are reported to be killed by membrane-pore formation and necrosis, a mechanism distinct from p53’s usual role as a transcription factor.
The published work is laboratory and preclinical — cultured cancer cells and animal models — and the selectivity and mechanism remain areas of active study and debate. There is no clinical trial and no approval; PNC-27 is a research compound, and this page is a research and educational reference.
The p53 (12–26) HDM-2-binding domain, fused to a membrane-penetrating sequence, targets membrane-expressed HDM-2 on cancer cells and induces transmembrane pore formation and necrosis; proposed to spare normal cells that lack membrane HDM-2.
Behind every vial of PNC-27 is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how PNC-27, specifically, is brought into being.
PNC-27 begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
PNC-27 is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — PNC-27 plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of PNC-27 proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of PNC-27 — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
A ~32-residue chimeric peptide joining a p53 fragment to a membrane-penetrating sequence. The long, partly hydrophobic chain is aggregation-prone on the resin, so solid-phase synthesis of the full length is hard and deletion-sequence control dominates purity. A genuine spec needs mass spectrometry of the full construct, not just the p53 portion.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning PNC-27, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
A designed peptide combining a p53 fragment with a membrane-targeting sequence, studied for inducing necrosis in cancer cells in preclinical models.
By anchoring the p53 HDM-2-binding domain in the cell membrane and targeting membrane-expressed HDM-2 on cancer cells, causing pore formation and necrosis rather than acting through p53 transcription.
No — the evidence is cell-culture and animal-model work; its selectivity and mechanism are still under study. There is no clinical trial.
No. This page is a research and educational reference, not medical advice.
The active fragment of parathyroid hormone — a recombinant peptide that builds bone, exploiting a paradox: the same hormone resorbs bone when continuous, but builds it when pulsed.
ViewRecombinant 191-amino-acid human growth hormone — a folded protein biologic identical in sequence to pituitary GH, not a synthetic research peptide.
ViewThe downstream effector of growth hormone — a 70-amino-acid recombinant protein, structurally a cousin of proinsulin, that carries out most of GH’s growth signal.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.